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Background: In pediatric age the prevalence of obesity is high. Obese children who
do not have other risk factors than excess weight have been defined as “metabolically
healthy obese” (MHO).
Aim: The aim of this study is to evaluate, in a population of obese children, the prevalence
of the MHO and “metabolically unhealthy obese” (MUO) phenotype. Furthermore, we
evaluated the distribution of Uric Acid, HOMA index and Waist-Height ratio (W-Hr) in the
MHO and MUO sub-groups and the impact of these non-traditional risk factors on the
probability to be MUO.
Methods: In 1201 obese children and adolescents [54% males, age (±SD) 11.9 (±3.0)
years] weight, height, waist circumference, systolic (SBP) and diastolic (DBP) blood
pressure, pubertal status, glucose, insulin, HDL cholesterol, triglycerides and Uric Acid
serum values were assessed. MUO phenotype was defined as the presence of at least
one of the following risk factors: SBP or DBP ≥ 90th percentile, glycaemia ≥ 100 mg/dl,
HDL cholesterol<40mg/dl, triglycerides≥100mg/dl (children<10 years) or≥130mg/dl
(children ≥10 years). A multivariate logistic regression analysis was used to estimate the
association between MUO phenotype and non-traditional cardiovascular risk factors.
Results: The prevalence of the MUO status was high (61%). MUO subjects were more
often male, older and pubertal (p < 0.001). The levels of the three non-traditional risk
factors were significantly higher in MUO children compared to MHO children (p < 0.001)
and all of them were independent predictors of the fact of being MUO [OR 1.41 (95% CI
1.24–1.69); 1.15 (95% CI 1.06–1.23) and 1.03 (95% CI1.01–1.05) for Uric Acid, HOMA
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index and W-Hr, respectively]. About 15% of MHO subjects had serum Uric Acid, HOMA
index and W-Hr values within the highest quartile of the study population.
Conclusion: The prevalence of MUO subjects in a large pediatric population is high
and serum Uric Acid, HOMA index and W-Hr values are independent predictors of the
probability of being MUO. A non-negligible percentage of subjects MHO has high values
of all three non-traditional risk factors.
Keywords: children, metabolically healthy obesity, Uric Acid, HOMA index, waist-height ratio
INTRODUCTION
The increasing prevalence of obesity in children and adolescents
is becoming a global concern (1). Obesity is a complex, chronic
condition characterized by multiple causes and adverse health
consequences (2, 3) and it is associated with increase all-
cause mortality in adults (4). Excess weight in childhood is a
major risk factor for adulthood obesity (5) and increases the
risk of morbidity and mortality later in life (6). Not all obese
individuals show an equal health risk. Metabolically healthy
obesity (MHO) is defined as a condition in which, despite
the significant excess weight, traditional risk factors as insulin
resistance (IR), dyslipidemia, and hypertension are not present
(7–10), contrary to what occurs in the metabolically unhealthy
obesity (MUO) condition.
The MHO phenotype has been described since the
1980s (11). For adults MHO is generally defined as a
condition in which metabolic syndrome (MetS) factors are
absent (2, 12).
For children and adolescents, there is still no universally
accepted definition of MetS (13, 14). For this reason, the
American Academy of Pediatrics recommended to focus on
the concept of cardiometabolic risk factor clustering, rather
than on the presence of MetS to define MHO in pediatric age
(15). Recently, a consensus of international experts proposed
a definition of MHO including cutoff values for high density
lipoprotein-cholesterol [>40 mg/dl, triglycerides ≤150 mg/dl),
systolic and diastolic blood pressure (≤ 90th percentile), and a
measure of glycaemia (16).
In adulthood, individuals with MUO show increased
mortality rates and cardiovascular risk compared to obese
individuals with normal metabolic profiles (17). It is therefore
possible that children and adolescents with the MUO phenotype
may have higher cardiovascular and mortality risk compared to
MHO subjects when they become adults.
The aims of the present study are (i) to determine the
prevalence of the MUO phenotype in a population sample of
obese Italian children and adolescents referred to secondary level
Clinical Centers, (ii) to evaluate the distribution of Waist-Height
ratio (W-Hr), Homeostatic Model Assessment (HOMA) index
of insulin resistance and serum Uric Acid values in MHO and
MUO children (iii) to investigate whether these non-traditional
cardiovascular risk factors are independent predictors of the
MUO phenotype, if added to the risk factors already present in
the definition.
METHODS
We studied a cohort of 1201 obese children and adolescents (4–
18 years) referred from January 2002 to August 2019 by their
primary care pediatricians to the IRCCS Istituto Auxologico
Italiano and to the International Center for the Assessment
of Nutritional Status, ICANS. Cardiovascular risk factors were
evaluated at Istituto Auxologico Italiano, IRCCS, Cardiologic
Unit. Inclusion criteria for the study were: (1) age ≤18
years (2) informed consent obtained from parents or legal
representatives to participate in the study. Exclusion criteria
were: (1) syndromic obesity; (2) dysthyroidism; (3) diabetes; (4)
congenital cardiovascular diseases (5) any form of secondary
hypertension (6) presence of chronic kidney disease and (7)
treatment with antihypertensive drugs, lipid-lowering drugs, and
glucose altering medications such as metformin.
The study protocol was approved by the local institutional
ethics committee and conformed to the ethical guidelines of the
1975 Declaration of Helsinki.
Anthropometric Parameters and Blood
Pressure
Anthropometric measurements were taken following
international guidelines (18). Weight was measured with
700 SECA gram scale and height with 417 SECA stadiometer
( R©SECA Medical Measuring Systems and scales, Birmingham
UK), approximated to the nearest 100 g and 0.5 cm, respectively.
BMI was calculated as weight (kg)/height (m)2. BMI z-scores
were calculated using the Centers for Disease and Control
prevention charts available at http://www.cdc.gov/nchs/. Weight
class (Obesity) was defined according to the International
Obesity Task Force classification (19). Waist circumference
was measured in standing position at the midpoint between
the last rib and the iliac crest with a non-stretch tape to the
nearest 0.5 cm. Waist–height ratio was calculated dividing
WC by height obtaining a pure number. Pubertal stage was
assessed by a medical examination and children were classified
into two categories: pre-pubertal and pubertal according to
Tanner (20). Blood pressure (BP) was measured using an
aneroid sphygmomanometer with the appropriate cuff for the
child’s upper arm size (Heine GAMMA R© G7, Germany). The
sphygmomanometer was calibrated before starting the study and
once a month thereafter with a mercury sphygmomanometer.
Systolic BP (SBP) was defined by the first Korotkoff sound
(appearance of sounds) and diastolic BP (DBP) was identified
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by the fifth Korotkoff sound (disappearance of sounds).
Measurements were performed after at least 5min of rest. BP
measures were taken 3 times (at 3–5min intervals). The average
of the two last SBP and diastolic BP (DBP measurements was
calculated. Systolic BP and DBP 90th percentiles were calculated
according to the nomograms of the National High Blood
Pressure Education Program (NHBPEP) Working Group on
High Blood Pressure in Children and Adolescents (21).
Biochemical Parameters
Fasting blood samples were drawn after a 12-h fasting period in
order and analyzed in the same morning. Glucose, triglycerides,
HDL- cholesterol, alanine transaminase (ALT), gamma-
glutamyl-transferase (GGT) and uric acid were measured by
means of an enzymatic method (Cobas Integra 400 Plus, Roche
Diagnostics, Rotkreuz, Switzerland), with intra-and inter-assay
CVs < 2%. Circulating insulin was measured in duplicate by
an autoanalyzer (Cobas e411 Hitachi, Roche Diagnostics). The
homeostatic model assessment-insulin resistance was calculated
as [fasting glucose (mg/dL)× fasting insulin (mU/L)/405] (22).
MHO/MUO Definition
The following definition to identify MHO subjects was applied:
SBP and DBP <90th percentile by gender, age and height
percentile, glycaemia <100 mg/dl, HDL cholesterol >40 mg/dl,
triglycerides <100 mg/dl (children <10 years) or <130 mg/dl
(children≥10 years) (16).
MUO phenotype was defined as the presence of at least one
of the following risk factors: SBP or DBP≥ 90th percentile,
glycaemia>100 mg/dl, HDL cholesterol≤40 mg/dl, triglycerides
≥100 mg/dl (children <10 years) or ≥130 mg/dl (children
≥10 years).
In the proposed definition of MHO (16) it is not specified
which glycemia cut-off should be used. However, most of the
studies reviewed by the expert consensus used fasting glucose
<100 mg/dL. For this reason, we used the same value in our
study. The triglyceride cut-offs were based on the indications
of the National Cholesterol Education Program (NCEP) Expert
Panel on Cholesterol Levels in Children (23, 24). Since the
proposed definition of MHO suggests 150mg as a single cut-off
for triglycerides, we also performed a further analysis (sensitivity
analysis) by entering this triglyceride cut-off.
Statistical Method
Data analysis was conducted separately for male and female
subjects. Categorical variables were described by percentages
and continuous variables were reported as means and standard
deviations. Comparison across groups was performed by Chi-
square and T-test considering 0.05 as significance level to judge
p-values. Logistic regression was used to relate the binary status
(MHO orMUO) to explanatory variables through univariate and
multivariate models. The discrimination potential of explanatory
variables was investigated via receiver operating characteristic
curves. Data analysis and graphics was conducted by the STATA
16 software (StataCorp LLC 4905 Lakeway Drive College Station,
TX 77845 USA).
TABLE 1 | Characteristics of the study population by gender.
Variable Male
(n = 559)
Female
(n = 642)
Total p-value
Age years (±SD) 12.0 (±3.2) 11.8 (±2.7) 11.9 (±3.0) 0.135
Puberty (yes,%) 257 (46.0%) 420 (65.4%) 677 (56.4%) <0.001
BMI, kg/m2 (±SD) 32.0 (±4.6) 28.0 (±5.3) 30.5 (±5.3) <0.001
BMI z-score (±SD) 2.2 (±0.3) 2.3 (±0.3) 2.2 (±0.3) <0.001
SBP, mmHg (±SD) 111 (±13.8) 116 (±12.7) 113 ± (13.4) <0.0001
SBP z-score (±SD) 0.68 (±1.23) 0.40 (±1.18) 0.53 (±1.21) <0.0001
DBP, mmHg (±SD) 71 (±8.2) 70 (±8.1) 70.3 (±8.2) 0.030
DBP z-score (±SD) 0.63 (±0.72) 0.59 (±0.69) 0.61 (±0.70) <0.0001
Glycaemia, mg/dl
(±SD)
85.1 (±7.5) 83.5 (±7.3) 84.2 (±7.4) <0.001
Triglycerides, mg/dl
(±SD)
81.6 (±41.6) 82.6 (±39.3) 82.1 (±40.4) 0.699
HDL cholesterol,
mg/dl (±SD)
49.7 (±11.1) 49.0 (±10.5) 49.3 ± (10.8) 0.856
W-Hr,%, (±SD) 60.6 (±8.4) 59.4 (±7.4) 60.0 (±7.9) 0.016
Uric Acid, mg/dl)
(±SD), n = 1,082
5.1 (±1.5) 4.7 (±1.1) 4.9 (±1.3) <0.001
HOMA index (±SD),
n = 1,142
3.3 (±2.2) 3.3(±2.3) 3.3 (±2.3) 0.813
RESULTS
Table 1 shows the characteristics of the study population by
gender. About 46.0% of the subjects were male and 56% were
pubertal. Serum Uric Acid and W-Hr values were significantly
higher in males [5.1 (±1.5) vs. 4.7 (±1.0) mg/dl, p < 0.001 and
60.6 (±8.4) vs. 59.4 (±7.4)%, p= 0.016, respectively].
As expected, the pre-pubertal subjects were younger, more
sensitive to insulin, and had lower Uric Acid and W-Hr values
than pubertal, [age, 9.2 (±1.9) vs. 13.7 (±2.3) years, p < 0.001;
HOMA index 2.8 (±1.9) vs. 3.7 (±2.4), p < 0.001; Uric Acid 4.4
(±0.9) vs. 5.2 (±1.3) mg/dl, p < 0.001 and W-Hr58.0 (±7.0) vs.
61.0 (±8.0)%, p < 0.001].
Seven hundred and thirty-two subjects (61.0%) were MUO.
Table 2 shows the characteristics of the study population by
metabolic status. MUO subjects were more frequently male [OR
1.26 (95% CI 0.99–1.59), p = 0.053], and more often pubertal
[OR 2.0 (95% CI 1.56–2.55), p < 0.001] compared to MHO
children. The risk of being MUO increased with increasing age
[OR 1.14 (95% CI 1.09–1.18), per 1-year increment, p < 0.001].
Both SBP and DBP z-scores were higher in MUO compared to
MHO subjects (p< 0.001). Moreover, plasma values of glycaemia
and triglycerides were higher and those of HDL cholesterol
were lower in MUO children (p < 0.001). Serum Uric Acid
values were significantly higher in the MUO group than in the
MHO group [5.2 (±1.3) vs. 4.5 (±1.1) mg/dl, p < 0.001], as
well as those of HOMA index [3.7 (±2.4) vs. 2.8 (±1.8), p <
0.001] and W-Hr [61.2 (±8.1) vs. 58.0 (±7.2)%, p < 0.001].
It is interesting to note that MUO subjects were not different
from MHO subjects as far as the BMI z-score values were
concerned (p= 0.117).
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TABLE 2 | Characteristics of the study population by metabolic status.
Variable MHO
(n = 469)
MUO
(n = 732)
p-value
Male (%) 202 (36.1) 357 (63.9) 0.053
Female (%) 267 (41.6) 375 (58.4)
Age years (±SD) 11.2 (±3.0) 12.3 (±3.0) <0.001
Puberty (yes,%) 222 (47.3) 455 (62.2) <0.001
BMI, kg/m2 (±SD) 30.0 (±5.7) 30.7 (±5.0) 0.025
BMI z-score (±SD) 2.3 (±0.3) 2.2 (±0.3) 0.117
SBP, mmHg (±SD) 105.6 (±9.4) 118.3 (±13.3) <0.001
SBP z-score (±SD) −0.12 (±0.89) 0.95 (±1.21) <0.001
DBP, mmHg (±SD) 66.9 (±6.7) 72.5 (±8.3) <0.001
DBP z-score (±SD) 0.32 (±0.54) 0.80 (±0.73) <0.001
Glycaemia, mg/dl (±SD) 83.2 (±6.7) 84.9 (±7.8) <0.001
Triglycerides, mg/dl (±SD) 65.0 (±20.8) 96.0 (±46.6) <0.001
HDL cholesterol, mg/dl (±SD) 53.4 (±9.2) 46.7 (±11.0) <0.001
W-Hr, % (±SD), n = 1,138 58.0 (±7.2) 61.2 (±8.1) <0.001
Uric Acid, mg/dl (±SD), n = 1,082 4.5 (±1.1) 5.2 (±1.3) <0.001
HOMA index (±SD), n = 1,142 2.8 (±1.8) 3.7 (±2.4) <0.001
TABLE 3 | Distribution of risk factors among MUO children by gender.
Females
(n = 375)
Males
(n = 357)
Total
(n = 732)
Systolic blood pressure ≥90th
percentile n (%)
138 (36.8%) 174 (48.7%) 312 (42.6%)
Diastolic blood pressure ≥90th
percentile n (%)
118 (31.5%) 125 (35.0%) 243 (33.2%)
HDL cholesterol <40 mg/dl n (%) 125 (33.3%) 118 (33.0%) 243 (33.2%)
Triglycerides ≥100/130 mg/dl n (%) 168 (44.8%) 144 (40.3%) 312 (42.6%)
Glycaemia ≥100 mg/dl n (%) 29 (7.7%) 33 (9.2%) 62 (8.5%)
Among MUO children, 389 (53.1%) presented only one risk
factor, 266 (36.3%) 2 risk factors, 57 (7.8%) 3 risk factors and
only 20 (2.7%) had all four risk factors of the definition of the
MUO phenotype. Table 3 shows the risk factor distribution (SBP
≥ 90th percentile, DBP ≥ 90th percentile, low HDL cholesterol,
high triglycerides and high glycaemia) among MUO children
according to gender. Hypertriglyceridemia and high SBP were
the most represented risk factor (42.6%), subjects with DBP≥
90th percentile and those with low HDL were also frequent
(33.2%). Instead, a low prevalence of elevated glycaemia was
observed (8.5%).
After adjustment for gender, age and pubertal status, Uric Acid
values [OR 1.53 (95% CI 1.35–1.74), p < 0.001], those of HOMA
index [OR 1.28 (95% CI 1.12–1.30), p < 0.001] and those of
W-Hr [OR 102.23 (95% CI 15.80–661.51), p < 0.001] were all
independent predictors of the probability of being MUO.
When Uric Acid, HOMA index and W-Hr were put together
in the logistic regression model, all three variables maintained
their predictive power on the probability of being MUO and
the result did not change after adjustment for gender, age and
pubertal status. The probability of being classified as MUO
TABLE 4 | Effect of Uric Acid, HOMA index and W-Hr on the risk to be MUO by a
multiple logistic regression.
Variable Odds ratio 95% Confidence interval p-value
UNIVARIATE ANALYSIS
Uric Acid (mg/dl) 1.48 (1.30–1.67) <0.001
HOMA index 1.15 (1.07–1.24) <0.001
W-Hr (%) 1.03 (1.01–1.05) 0.001
MULTIVARIATE ANALYSIS
Gender (male) 1.26 (0.95–1.68) 0.110
Puberty (yes vs. no) 1.32 (0.89–1.95) 0.161
Age (years) 1.01 (0.95–1.08) 0.614
Uric Acid (mg/dl) 1.41 (1.24–1.62) <0.001
HOMA index 1.15 (1.06–1.23) <0.001
W-Hr (%) 1.03 (1.01–1.05) 0.006
increased by 41% for each 1 mg/dl increase in serum Uric Acid,
by 15% for each increment of 1 unit of HOMA index and by 3%
for each percentage unit of W-Hr (Table 4).
Figure 1 shows the three ROC curves related to the sensitivity
and specificity of Uric Acid (Panel 1), HOMA index (Panel 2) and
W-Hr (Panel 3) in the prediction of being a MUO subject. The
areas under ROC curves were 0.66, 0.64, and 0.61 for Uric Acid,
HOMA index and W-Hr, respectively.
A high percentage of MUO children showed Uric Acid,
HOMA index and W-Hr values within the highest quartile. In
the MUO group the percentage of children who had Uric Acid,
HOMA index and W-Hr values within the fourth quartile was
about twice the percentage observed in the MHO group (p <
0.001) (Table 5).
The sensitivity analysis performed by entering 150 mg/dl as
single triglyceride cut-off confirmed the independent predictive
value of Uric Acid, HOMA index and W-Hr on the risk of
being MUO. With the additional analysis, BMI z-score was
greater in MHO compared to MUO subjects, however the
difference disappeared at multivariate analysis. Furthermore,
male gender was an independent predictor of MUO phenotype
(Supplementary Tables 2–5). The areas under ROC curves did
not change with the sensitivity analysis.
DISCUSSION
The main results of our study are: (i) the prevalence of MUO
subjects in a large pediatric population is high (about 60%) (ii)
three risk factors not included in the definition of MHO (serum
Uric Acid, HOMA index and W-Hr) are significantly higher
in MUO children compared to MHO children and all three
are independent predictors of the possibility of being MUO iii)
considering the study population, a non-negligible percentage of
MHO subjects has values of serum Uric Acid, HOMA index and
W-Hr within the highest quartile.
The prevalence of the MHO phenotype in children described
in the literature varies from 20 to 68%, but it should be
emphasized that the MHO definitions used in the different
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FIGURE 1 | Receiver Operating Characteristic (ROC) curve of Uric Acid
(mg/dl) (Panel 1), HOMA index (Panel 2), and W-Hr (Panel 3) to detect the
condition of metabolic unhealthy obesity.
TABLE 5 | Children with Uric Acid, HOMA index and W-Hrvalues within the fourth
quartile in MHO/MUO groups.
Variable 4th quartile n (%*) p-value
MHO n = 496 MUO n = 732
Uric Acid (mg/dl) 65 (15.1) 227 (34.8) <0.001
HOMA index 70 (15.2) 216 (31.6) <0.001
W-Hr (%) 76 (17.2) 210 (30.2) <0.001
*Percentages are calculated on the total number of subjects where the variable
was assessed.
studies are not always the same. Moreover, in most cases these
studies are performed in populations composed of a relatively
small number of children (2). The prevalence of MHO subjects
we found in a large sample is higher than that described by other
authors (25). However, it must be considered that this sample
does not originate from a population screening. These young
patients, in fact, are referred to us by their family pediatricians,
when they have some difficulty in managing them. Our clinics, in
fact, constitute a second-level clinical care center. For this reason,
we cannot consider the study population as representative of
the Italian pediatric population. The prevalence of individual
risk factors in our sample of MUO children is similar to that
reported in a previous study performed in a large pediatric
population (26).
Previous studies demonstrated that all three non-traditional
cardiovascular risk factors considered have a significant and
positive association with BP z-scores and the presence of
arterial hypertension in pediatric populations (27–31). The
well-documented association of hyperuricemia with metabolic
syndrome in adults (32) agrees with the observation made
in a cohort of children with severe obesity (33), and further
supports the role for Uric Acid as an independent risk factor
for cardiovascular diseases. Several studies show that MUO
subjects have a higher degree of obesity (i.e., a BMI z-score)
than MHO subjects (34, 35). In our population, on the contrary,
there is no difference in BMI z-score values between MHO
children and MUO children. Despite this, W-Hr is significantly
higher in MUO subjects, suggesting the presence of a different
distribution of abdominal adipose tissue in this sub-group. In
children, a high W-Hr value is associated with alterations of a
series of cytokines that can lead to negative consequences on the
cardiovascular system (36–38). In the present study population,
although there are no significant differences in BMI z-score
between the two phenotypes, the values of HOMA index are
significantly higher in MUO children. This finding suggests a
close relationship between visceral fat and insulin resistance, a
known cardiovascular risk factor (29). The INTERHEART study,
a case-control study that looked at 29,972 patients in 52 countries,
showed that the relationship between waist circumference and
waist-to-hip ratio and myocardial infarction is stronger than the
relationship between myocardial infarction and BMI (39).
The abovementioned evidence helps us to interpret our
results, suggesting a series of reasons why, individually,
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the non-traditional cardiovascular risk factors considered are
associated with the MUO phenotype. However, our study
provides an additional observation concerning these data. As
a matter of fact, in our population serum Uric Acid, HOMA
index and W-Hr may be helpful, independently of each other,
to identify among obese children those showing the MUO
phenotype. It is important to underline that 15% of children
with the MHO phenotype show high values of one or more of
the three non-traditional cardiovascular risk factors. It has been
shown that obesity is a powerful predictor of cardiac hypertrophy
in children, regardless of the presence of hypertension (40). Di
Bonito et al. described a prevalence of hepatic steatosis of 36.5%
and a proportion of 56.0% of left ventricular hypertrophy in
a pediatric MHO population (41). Moreover, Dangardt et al.
showed, in a large population of children and adolescents, that
persistence of high total fat mass during adolescence, assessed
using dual-energy x-ray absorptiometry, was positively associated
with increased arterial stiffness, assessed by carotid-femoral pulse
wave velocity. This adverse association (with arterial stiffness)
was absent with BMI z-score (42). It is therefore conceivable that
evenMHO subjects cannot be considered truly “healthy” and that
they may present initial organ damage of some kind or that they
may, over time, become hypertensive.
The definition of an MHO phenotype was created in the
adult population, in which it is possible to evaluate the incidence
of cardiovascular events and mortality, and to compare this
between MHO and MUO patients (17). Of course, this cannot
be done in the pediatric population. Moreover, in adults,
obesity is frequently a stable condition, not of recent onset,
and may therefore exert its negative effects over time. In
children, instead, the presence of obesity can be transient and
represents a condition with a more recent clinical history than
in adults. However, Reinehret al. demonstrated that, in their
large pediatric population, after 1 year of follow-up, the majority
of the MHO children remained MHO (68.0%) (26). Our data
show that older and post-pubertal subjects, in whom it can
be assumed that obesity has been present for longer, are more
frequently MUO. This would suggest that it takes some time for
metabolic alterations to occur. Furthermore, for what regards
non-traditional risk factors, it should be noted that also insulin
resistance and Uric Acid serum values increase with age and
puberty. Our multivariate model however, shows an association
between MHO phenotype and these non-traditional risk factors
independent of the age of the child, suggesting the importance
of a very early intervention. It is reasonable to hypothesize
that a part of the children who present the MHO phenotype
could become MUO adults; this could be influenced by their
genetic predisposition, as well as by eating habits and lifestyle
(43). Only prospective studies will allow us to understand what
percentage of children who are obese in childhood remain obese
in adulthood and how many of the subjects showing the MHO
phenotype in childhood, continue to be MHO even when they
become adults.
A strength of the study is the size of the study-population,
but a limitation is the cross-sectional design. For this reason, we
can only describe associations between cardiovascular risk factors
and the presence of MU phenotype, but we cannot say whether
or not there is a cause/effect relationship. In addition, our sample
is made up of subjects referred to a Center for the prevention
and treatment of cardiovascular risk in pediatric age and may not
represent the totality of obese children.
In conclusion, on the one hand distinguishing between the
MHO and MUO phenotype in children can be potentially useful,
as it allows the pediatrician to more closely follow-up the subjects
with highest cardiovascular risk (8). The definition proposed by
Damanhoury et al. (16) however, can lead to an underestimation
of the number of obese children actually at risk, as obesity
per se can lead to early organ damage even in the absence of
metabolic alterations (40, 41). Furthermore, the definition does
not cover all potential cardiovascular risk factors, such as insulin
resistance, high levels of Uric Acid and visceral adiposity (44).
In our opinion, the definition proposed by Damanhoury et al.
(16) is a bit limiting and pediatricians would need amore detailed
definition to identify obese MUO subjects.
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